Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study

2017 ◽  
Vol 32 (4) ◽  
pp. e2583 ◽  
Author(s):  
Farzin Rezaei ◽  
Bita Mesgarpour ◽  
Alireza Jeddian ◽  
Atefeh Zeionoddini ◽  
Payam Mohammadinejad ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial

2020 ◽  
Vol 34 (5) ◽  
pp. 506-513 ◽  
Author(s):  
Ehsan Moazen-Zadeh ◽  
Samaneh Bayanati ◽  
Kimia Ziafat ◽  
Farzin Rezaei ◽  
Bita Mesgarpour ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adjunctive Therapy ◽  
Negative Symptoms ◽  
Rating Scale ◽  
Chronic Schizophrenia ◽  
Mean Difference ◽  
Double Blind ◽  
General Psychopathology ◽  
Double Blind Placebo ◽  
End Point

Introduction and objectives: Vortioxetine, a novel antidepressant, may be an interesting candidate for adjunctive therapy of schizophrenia. Our primary objective was to investigate the effect of vortioxetine on negative symptoms, with the assessment of positive, general psychopathology and total symptoms as our secondary goal. Methods: This was an eight-week randomised, double-blind, placebo-controlled, parallel-group clinical trial, in which 78 inpatients with chronic schizophrenia were stabilised with risperidone (4–6 mg/day) for two months before being assigned to adjunctive vortioxetine (10 mg b.i.d.) or placebo. The patients were assessed using the Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Symptom Rating Scale and Hamilton Depression Rating Scale during the study course. All participants had a PANSS negative symptoms subscale score of ⩾16 at baseline. Sixty-eight patients completed the trial. Results: Vortioxetine improved the negative symptoms score as the primary outcome and total PANSS score as a secondary outcome significantly better than placebo from baseline to end point at week 8, accompanied by significant time × treatment interactions and effect sizes (negative symptoms: mean difference (95% confidence interval (CI)) = −1.82 (−2.73 to −0.92); total scores: mean difference (95% CI) = −2.09 (−3.16 to −1.01). No significant difference was detected for changes in positive symptoms score or PANSS general psychopathology score as the other secondary outcomes from baseline to end point between the two treatment arms. The incidence of adverse events was comparable between groups. Conclusions: This is the first study to provide evidence for the therapeutic effect of vortioxetine on negative symptoms as an adjunctive to treatment with antipsychotics in patients with schizophrenia.

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: A double-blind placebo-controlled study

2004 ◽  
Vol 36 (05) ◽  
Author(s):  
MC Jockers-Scherübl ◽  
A Bauer ◽  
F Godemann ◽  
FM Reischies ◽  
F Selig ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study

2016 ◽  
Vol 49 (04) ◽  
pp. 162-169 ◽  
Author(s):  
M.-R. Nikbakhat ◽  
S. Arabzadeh ◽  
A. Zeinoddini ◽  
Z. Khalili ◽  
F. Rezaei ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Nilvadipine Is Effective for Chronic Schizophrenia in a Double-Blind Placebo-Controlled Study

1996 ◽  
Vol 16 (6) ◽  
pp. 437-439 ◽  
Author(s):  
Kazuo Yamada ◽  
Shigenobu Kanba ◽  
Iyoko Ashikari ◽  
Kimio Ohnishi ◽  
Gohei Yagi ◽  
...  
Keyword(s):  
Chronic Schizophrenia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document